Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness

Slide: 22 of 34

Triple Therapy With Telaprevir Versus Dual Therapy in Patients With HCV Genotype 1 Infection: Adverse Effects

In three trials, a 24-week treatment regimen of triple therapy (pegylated interferon alfa [2a or 2b] plus ribavirin plus telaprevir) for 12 weeks followed by dual therapy (pegylated interferon alfa-2a plus ribavirin) for another 12 weeks was associated with an increased risk of anemia (3 trials; pooled relative risk [RR], 1.3; 95-percent confidence interval [95% CI], 1.1 to 1.5) and of rash (3 trials; pooled RR, 1.4; 95% CI, 1.1 to 1.7) when compared with a 48-week regimen of dual therapy (pegylated interferon alfa-2a plus ribavirin). Among patients randomized to the 24-week regimen containing telaprevir, one-third to two-thirds of patients experienced a rash (7–10% experienced a severe rash), and 27–91 percent experienced anemia (4–11% experienced severe anemia). There was no difference in risk of withdrawal due to adverse events. The strength of evidence for this finding was rated moderate.